Key Takeaway
The FDA drug shortage list has become one of the most important factors in access to compounded GLP-1 medications. This FDA drug shortage compounding resource covers the important information you need to make informed decisions.
The FDA drug shortage list has become one of the most important factors in access to compounded GLP-1 medications. This FDA drug shortage compounding resource covers the important information you need to make informed decisions. Whether a drug like semaglutide or tirzepatide is listed as "in shortage" directly affects what compounding pharmacies can legally prepare.
Key Takeaways: - Understand what is the fda drug shortage list - Learn how shortages affect compounding rules - Understand what happens when a shortage ends - Learn how to stay informed
If you're using or considering compounded GLP-1 treatment, understanding how FDA drug shortage compounding rules work helps you plan ahead and avoid disruptions.
What Is the FDA Drug Shortage List?
The FDA maintains a public list of medications currently experiencing supply shortages in the United States. The list is updated regularly and tracks both the status of each shortage and the reasons behind it.
Drug shortages happen for many reasons: - Manufacturing problems at the original manufacturer - Raw material supply issues - Unexpected demand spikes - Quality control issues leading to production halts - Regulatory actions against manufacturers
"Compounding pharmacies serve a critical role in healthcare, but patients need to understand the difference between a properly regulated 503B facility and an unregulated operation. Ask about PCAB accreditation and third-party testing.") Dr. Scott Brunner, PharmD, Alliance for Pharmacy Compounding
When a drug is listed as "currently in shortage," it means the total supply available in the US isn't enough to meet patient demand through normal commercial channels.
The list is publicly available on the FDA's website. Anyone can check it. And for compounding pharmacies, this list has enormous legal significance.
How Shortages Affect Compounding Rules
Under normal circumstances, compounding pharmacies face restrictions on producing copies of commercially available FDA-approved drugs. The rules are designed to prevent compounding from becoming a back door around the FDA approval process.
View data table
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
But when a drug is on the shortage list, those restrictions loosen. Here's how.
During a shortage: Both 503A and 503B compounding pharmacies can prepare compounded versions of the shortage drug. This provision exists to protect patient access. If patients can't get the commercially manufactured version, compounded versions fill the gap.
After a shortage ends: The rules tighten again. The specific impact depends on the type of pharmacy. 503A pharmacies may still compound the drug on a patient-specific basis under certain conditions. 503B outsourcing facilities face more immediate restrictions on producing copies of the now-available drug.
Transition periods. When the FDA resolves a shortage, there may be a transition period. The FDA has sometimes provided guidance on how quickly pharmacies must wind down production of drugs coming off the shortage list.
This framework directly affects access to compounded and tirzepatide. Understanding the current shortage status helps you and your provider plan your treatment.
Free Download: Compounding Pharmacy Verification Checklist Stay informed about your pharmacy's compliance during shortage transitions. This checklist helps you verify that your pharmacy is operating within current regulations. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
What Happens When a Shortage Ends
This is the question that concerns many patients using compounded GLP-1 medications. Here's what to expect.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Your existing prescription is still valid. A prescription written by your licensed provider based on a clinical evaluation remains valid regardless of shortage status changes. Your provider prescribed what's clinically appropriate for you.
Pharmacy operations may change. The pharmacy may need to adjust how it sources ingredients or structures its compounding based on the updated regulatory field. Some pharmacies may stop offering certain compounded products.
Compounding may continue under certain conditions. Even outside of a shortage, 503A pharmacies can compound medications when there's a clinical need) for example, when a patient needs a different dosage form, concentration, or formulation than what's commercially available. Your provider can determine if this applies to you.
Communication from your platform. If you're getting treatment through FormBlends or a similar platform, expect communication about any changes that affect your care. Responsible platforms plan ahead for these transitions.
Treatment continuity. Your provider's primary obligation is to your health. They'll work with you to ensure continuity of care, whether that means continued compounded medication (if legally available), a switch to a commercially available product, or another treatment approach.
The most important thing you can do is maintain a relationship with your so you're never caught off guard.
How to Stay Informed
You don't need to become a regulatory expert, but staying aware of the basics helps.
Check the FDA shortage list. Visit the FDA's drug shortage database periodically. Search for the medications you're taking. The site shows current status and any expected resolution dates.
Ask your provider. During check-ins, ask your provider about any regulatory changes that might affect your treatment. A good provider stays current on these issues.
Follow your platform's updates. Platforms like FormBlends communicate with patients about regulatory changes that affect services. Make sure your contact information is current so you receive these updates.
Don't panic at headlines. Media coverage of drug shortages and compounding regulations can be sensationalized. Not every regulatory change means your medication will disappear. Get the facts before making decisions.
For a broader understanding of your treatment options and costs, explore the and .
Frequently Asked Questions
Is semaglutide currently on the FDA drug shortage list?
The FDA drug shortage list is updated regularly. Check the FDA's website directly for the most current status. Your healthcare provider and telehealth platform can also provide up-to-date information about availability.
Can I stockpile compounded medication in case the shortage ends?
This isn't recommended. Compounded medications have limited beyond-use dates, and stockpiling beyond what you need could mean using expired medication. Your provider will prescribe appropriate quantities based on your treatment plan.
Will my compounded medication become illegal if the shortage ends?
Not necessarily. Compounding regulations are nuanced. 503A pharmacies may still compound certain medications under specific conditions even outside of a shortage. Your provider will advise you on the best path forward based on current regulations.
How long do drug shortages typically last?
Drug shortages can last anywhere from weeks to years, depending on the cause. Manufacturing issues may resolve relatively quickly. Demand-driven shortages tied to rapid market growth (as with GLP-1 medications) can persist longer.
What's the difference between a drug being "in shortage" and "resolved"?
"In shortage" means the total available supply isn't meeting demand. "Resolved" means supply has returned to normal levels and can meet patient demand through regular commercial channels. The FDA makes this determination based on manufacturer-reported data.
What's Your Next Move?
You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple (answer a few questions and get a personalized recommendation.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections) United States, 2012. MMWR. 2012;61(41):839-842.
- U.S. Food and Drug Administration. Drug Quality and Security Act (DQSA). Public Law 113-54. November 27, 2013.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
This article is for educational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →